Core Viewpoint - Agomab Therapeutics NV has announced the pricing of its initial public offering (IPO) of 12,500,000 American Depositary Shares (ADSs) at a price of $16.00 per ADS, aiming to raise gross proceeds of $200 million before expenses [1][2]. Company Overview - Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, particularly targeting chronic fibrotic indications with high unmet medical need [6]. - The company's product candidates aim to target established pathways and utilize validated modalities to enhance efficacy while minimizing systemic toxicities, addressing limitations of previous therapeutic approaches [6]. IPO Details - The ADSs are set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AGMB" on February 6, 2026, with the offering expected to close on February 9, 2026, pending customary closing conditions [2]. - J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are serving as joint book-running managers for the offering [2]. - Agomab has granted underwriters a 30-day option to purchase an additional 1,875,000 ADSs at the IPO price [1]. Regulatory Information - A registration statement for the offering was filed with the Securities and Exchange Commission and became effective on January 30, 2026, with the offering being made solely by means of a prospectus [3].
Agomab Announces Pricing of Initial Public Offering